Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
In the world economic growth, the Biopharmaceuticals Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Biopharmaceuticals market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, SMI analysts believe that in the next few years, Biopharmaceuticals market size will be further expanded, we expect that by 2024, The market size of the Biopharmaceuticals will reach XXX million $.
Biopharmaceuticals, also known as a biologics, or biological medical products, are pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources.
Increasing approval and launch of orphan drugs is drugs is expected to propel growth of the global biopharmaceuticals market over the forecast period. For instance, according to Pharmaceutical Research and Manufacturers of America, over 750 orphan drugs were approved in the U.S. in 2018, compared to over 600 in 2017.
Moreover, increasing R&D of biopharmaceuticals for the treatment of various types of cancers is also expected to aid in growth of the market. For instance, in March 2020, Jiangsu Alphamab Biopharmaceuticals Co., Ltd. entered a clinical supply agreement with Pfizer Inc. to advance a clinical study to investigate KN026 in combination with Ibrance (palbociclib), an oral CDK4/6 inhibitor, in patients with previously-treated locally advanced and/or metastatic HER2-positive breast cancer.
Decreasing healthcare cost due to use of biopharmaceuticals is expected to offer lucrative growth opportunities for players in the global biopharmaceuticals market. For instance, according to Pharmaceutical Research and Manufacturers of America, the total cumulative savings of Hepatitis C treatment since the introduction of highly effective interferon-free direct-acting antivirals are expected to reach US$ 12 billion by 2020. Moreover, increasing prevalence of chronic disorders is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
The current pandemic of COVID-19 has led manufacturers to focus on developing biopharmaceuticals for the disease. For instance, in April 2020, Ansun Biopharma, Inc. announced that investigator-initiated trial of novel COVID-19 treatment with DAS181, a recombinant sialidase with broad antiviral properties, demonstrated positive results.
Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in April 2020, Samsung Biologics signed a contract developing organization agreement with PharmAbcine, a biotechnology company, for developing and manufacturing the PMC-402 pipeline.
Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in August 2018, Amicus Therapeutics received the U.S. Food and Drug Administration approval for Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.
Key Takeaways:
- Increasing approval and launch of orphan drugs is drugs is expected to propel growth of the global biopharmaceuticals market over the forecast period
- Major players operating in the global biopharmaceuticals market include, F. Hoffmann-La Roche AG, Amgen, AbbVie Inc., Sanofi S.A, Aventis Pharma, Johnson & Johnson, Pfizer, Inc., Novo Nordisk A/S, Eli Lilly and Company, Novartis International AG, Merck & Co., Inc. Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Ansun Biopharma, Inc., Samsung Biologics, and Amicus Therapeutics
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers. If you need more information, please contact SMI
Section 1: Definition
Section (2 3): Manufacturer Details
➟ Roche
➟ Amgen
➟ AbbVie
➟ Sanofi-Aventis
➟ Johnson & Johnson
➟ Pfizer
➟ Novo Nordisk
➟ Eli Lilly
➟ Novartis
➟ Merck
Section 4: Region Segmentation
➟ North America Country (United States, Canada)
➟ South America
➟ Asia Country (China, Japan, India, Korea)
➟ Europe Country (Germany, UK, France, Italy)
➟ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
➟ Monoclonal Antibodies
➟ Interferon
➟ Colony-Stimulating Factor
➟ Erythropoietin
Industry Segmentation:
➟ Tumor
➟ Diabetes
➟ Cardiovascular
➟ Hemophilia
Channel (Direct Sales, Distributor) Segmentation
➟ Section 8: Trend (2019-2024)
➟ Section 9: Product Type Detail
➟ Section 10: Downstream Consumer
➟ Section 11: Cost Structure
➟ Section 12: Conclusion
